Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of directors since June 2024. Published first on TheFly ...

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report had ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Thursday reported a loss of $30 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...

Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst expectations. Their annual revenue took a dip, dropping $14.5 million from the ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Unfortunately, Arcturus Therapeutics Holdings ...

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free ...